176 related articles for article (PubMed ID: 30448260)
1. Cancer-associated stroma significantly contributes to the mesenchymal subtype signature of serous ovarian cancer.
Zhang Q; Wang C; Cliby WA
Gynecol Oncol; 2019 Feb; 152(2):368-374. PubMed ID: 30448260
[TBL] [Abstract][Full Text] [Related]
2. High expression of fibroblast activation protein (FAP) predicts poor outcome in high-grade serous ovarian cancer.
Li M; Cheng X; Rong R; Gao Y; Tang X; Chen Y
BMC Cancer; 2020 Oct; 20(1):1032. PubMed ID: 33109151
[TBL] [Abstract][Full Text] [Related]
3. Stiffness increases with myofibroblast content and collagen density in mesenchymal high grade serous ovarian cancer.
Mieulet V; Garnier C; Kieffer Y; Guilbert T; Nemati F; Marangoni E; Renault G; Chamming's F; Vincent-Salomon A; Mechta-Grigoriou F
Sci Rep; 2021 Feb; 11(1):4219. PubMed ID: 33603134
[TBL] [Abstract][Full Text] [Related]
4. The Impact of Stroma Admixture on Molecular Subtypes and Prognostic Gene Signatures in Serous Ovarian Cancer.
Schwede M; Waldron L; Mok SC; Wei W; Basunia A; Merritt MA; Mitsiades CS; Parmigiani G; Harrington DP; Quackenbush J; Birrer MJ; Culhane AC
Cancer Epidemiol Biomarkers Prev; 2020 Feb; 29(2):509-519. PubMed ID: 31871106
[TBL] [Abstract][Full Text] [Related]
5. A cell-of-origin epigenetic tracer reveals clinically distinct subtypes of high-grade serous ovarian cancer.
Lo Riso P; Villa CE; Gasparoni G; Vingiani A; Luongo R; Manfredi A; Jungmann A; Bertolotti A; Borgo F; Garbi A; Lupia M; Laise P; Das V; Pruneri G; Viale G; Colombo N; Manzo T; Nezi L; Cavallaro U; Cacchiarelli D; Walter J; Testa G
Genome Med; 2020 Oct; 12(1):94. PubMed ID: 33121525
[TBL] [Abstract][Full Text] [Related]
6. Tumour microenvironment-based molecular profiling reveals ideal candidates for high-grade serous ovarian cancer immunotherapy.
Lu X; Ji C; Jiang L; Zhu Y; Zhou Y; Meng J; Gao J; Lu T; Ye J; Yan F
Cell Prolif; 2021 Mar; 54(3):e12979. PubMed ID: 33522069
[TBL] [Abstract][Full Text] [Related]
7. CCNE1 and BRD4 co-amplification in high-grade serous ovarian cancer is associated with poor clinical outcomes.
Petersen S; Wilson AJ; Hirst J; Roby KF; Fadare O; Crispens MA; Beeghly-Fadiel A; Khabele D
Gynecol Oncol; 2020 May; 157(2):405-410. PubMed ID: 32044108
[TBL] [Abstract][Full Text] [Related]
8. Morphologic and molecular correlates of EZH2 as a predictor of platinum resistance in high-grade ovarian serous carcinoma.
Reid BM; Vyas S; Chen Z; Chen A; Kanetsky PA; Permuth JB; Sellers TA; Saglam O
BMC Cancer; 2021 Jun; 21(1):714. PubMed ID: 34140011
[TBL] [Abstract][Full Text] [Related]
9. Better or worse? The prognostic role of the mesenchymal subtype in patients with high-grade serous ovarian carcinoma: A systematic review and meta-analysis.
Chen J; Shi X; Xiao L; Li Z; Li Z; Sun L
Cancer Med; 2022 Oct; 11(20):3761-3770. PubMed ID: 35434908
[TBL] [Abstract][Full Text] [Related]
10. Gene signature characteristic of elevated stromal infiltration and activation is associated with increased risk of hematogenous and lymphatic metastasis in serous ovarian cancer.
Yue H; Wang J; Chen R; Hou X; Li J; Lu X
BMC Cancer; 2019 Dec; 19(1):1266. PubMed ID: 31888563
[TBL] [Abstract][Full Text] [Related]
11. Multiomic Analysis of Subtype Evolution and Heterogeneity in High-Grade Serous Ovarian Carcinoma.
Geistlinger L; Oh S; Ramos M; Schiffer L; LaRue RS; Henzler CM; Munro SA; Daughters C; Nelson AC; Winterhoff BJ; Chang Z; Talukdar S; Shetty M; Mullany SA; Morgan M; Parmigiani G; Birrer MJ; Qin LX; Riester M; Starr TK; Waldron L
Cancer Res; 2020 Oct; 80(20):4335-4345. PubMed ID: 32747365
[TBL] [Abstract][Full Text] [Related]
12. Single-Cell RNA-Sequencing Atlas Reveals the Tumor Microenvironment of Metastatic High-Grade Serous Ovarian Carcinoma.
Deng Y; Tan Y; Zhou D; Bai Y; Cao T; Zhong C; Huang W; Ou Y; Guo L; Liu Q; Yin D; Chen L; Luo X; Sun D; Sheng X
Front Immunol; 2022; 13():923194. PubMed ID: 35935940
[TBL] [Abstract][Full Text] [Related]
13. Into the future: A pilot study combining imaging with molecular profiling to predict resectability in ovarian cancer.
Kumar A; Wang C; Sheedy SP; McCauley BM; Winham SJ; Ramus SJ; Anglesio MS; Kim B; Torres D; Keeney GL; Cliby WA; Goode EL
Gynecol Oncol; 2022 Sep; 166(3):508-514. PubMed ID: 35931468
[TBL] [Abstract][Full Text] [Related]
14. Utilizing digital pathology to quantify stromal caveolin-1 expression in malignant and benign ovarian tumors: Associations with clinicopathological parameters and clinical outcomes.
Saeed-Vafa D; Marchion DC; McCarthy SM; Hakam A; Lopez A; Wenham RM; Apte SM; Chen DT; Magliocco AM; Lancaster JM; Reid BM; Permuth JB
PLoS One; 2021; 16(11):e0256615. PubMed ID: 34813586
[TBL] [Abstract][Full Text] [Related]
15. Differential DNA methylation in high-grade serous ovarian cancer (HGSOC) is associated with tumor behavior.
Reyes HD; Devor EJ; Warrier A; Newtson AM; Mattson J; Wagner V; Duncan GN; Leslie KK; Gonzalez-Bosquet J
Sci Rep; 2019 Nov; 9(1):17996. PubMed ID: 31784612
[TBL] [Abstract][Full Text] [Related]
16. Intratumor heterogeneity and homologous recombination deficiency of high-grade serous ovarian cancer are associated with prognosis and molecular subtype and change in treatment course.
Takaya H; Nakai H; Sakai K; Nishio K; Murakami K; Mandai M; Matsumura N
Gynecol Oncol; 2020 Feb; 156(2):415-422. PubMed ID: 31785864
[TBL] [Abstract][Full Text] [Related]
17. High-grade serous tubo-ovarian cancer refined with single-cell RNA sequencing: specific cell subtypes influence survival and determine molecular subtype classification.
Olbrecht S; Busschaert P; Qian J; Vanderstichele A; Loverix L; Van Gorp T; Van Nieuwenhuysen E; Han S; Van den Broeck A; Coosemans A; Van Rompuy AS; Lambrechts D; Vergote I
Genome Med; 2021 Jul; 13(1):111. PubMed ID: 34238352
[TBL] [Abstract][Full Text] [Related]
18. WNT Signaling Driven by R-spondin 1 and LGR6 in High-grade Serous Ovarian Cancer.
Lee S; Jun J; Kim WJ; Tamayo P; Howell SB
Anticancer Res; 2020 Nov; 40(11):6017-6028. PubMed ID: 33109540
[TBL] [Abstract][Full Text] [Related]
19. Combined image and genomic analysis of high-grade serous ovarian cancer reveals PTEN loss as a common driver event and prognostic classifier.
Martins FC; Santiago Id; Trinh A; Xian J; Guo A; Sayal K; Jimenez-Linan M; Deen S; Driver K; Mack M; Aslop J; Pharoah PD; Markowetz F; Brenton JD
Genome Biol; 2014 Dec; 15(12):526. PubMed ID: 25608477
[TBL] [Abstract][Full Text] [Related]
20. FBLN5 is targeted by microRNA‑27a‑3p and suppresses tumorigenesis and progression in high‑grade serous ovarian carcinoma.
Li R; Wu H; Jiang H; Wang Q; Dou Z; Ma H; Yan S; Yuan C; Yang N; Kong B
Oncol Rep; 2020 Nov; 44(5):2143-2151. PubMed ID: 32901854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
